Top-News
Biotechnologie USA

Sangamo Therapeutics Inc Aktie

Aktie
WKN:  936386 ISIN:  US8006771062 US-Symbol:  SGMO
1,8708 €
+0,0266 €
+1,44%
08:00:11 Uhr
Handeln Depot/Watchlist
Aktienanzahl *
177,35 Mio.
Marktkapitalisierung *
362,84 Mio. €
Streubesitz
59,08%
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 07.03.2024

Sangamo Therapeutics Inc News

19.11.24 - Businesswire
Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational ...
12.11.24 - Businesswire
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported business highlights and third quarter 2024 financial results.
04.11.24 - Businesswire
Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its third quarter 2024 financial ...
22.10.24 - Businesswire
Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the outcome of a recent successful interaction with the U.S. FDA, providing a clear ...
27.02.23 - PR Newswire
Thinking about buying stock in Broadmark Realty Capital, Seagen, Sangamo Therapeutics, Li Auto, or Bed Bath & Beyond?
Thinking about buying stock in Broadmark Realty Capital, Seagen, Sangamo Therapeutics, Li Auto, or Bed Bath & Beyond? PR Newswire
09.07.19 - The Motley Fool
BB-Biotech-Beteiligung explodiert: Was bedeutet das für die Dividendenperle?
Die Aktie von BB Biotech (WKN: A0NFN3) wird von vielen Investoren sehr geschätzt. Einmal natürlich aufgrund der spannenden Dividendenpolitik. Denn die Beteiligungsgesellschaft ...
21.06.19 - PR Newswire
Sangamo Announces Upcoming Presentation Of Investigational SB-525 Hemophilia A Gene Therapy Data At ISTH 2019
Sangamo Announces Upcoming Presentation Of Investigational SB-525 Hemophilia A Gene Therapy Data At ISTH 2019 PR Newswire
15.05.19 - PR Newswire
Sangamo Therapeutics Announces Presentations At Upcoming Scientific, Medical And Investor Conferences
Sangamo Therapeutics Announces Presentations At Upcoming Scientific, Medical And Investor Conferences Hemophilia A SB-525 gene therapy clinical data accepted for oral ...
10.05.19 - PR Newswire
Sangamo Therapeutics Announces Participation In The Bank Of America Merrill Lynch 2019 Health Care Conference
Sangamo Therapeutics Announces Participation In The Bank Of America Merrill Lynch 2019 Health Care Conference PR Newswire
08.05.19 - PR Newswire
Sangamo Therapeutics Reports First Quarter 2019 Financial Results
Sangamo Therapeutics Reports First Quarter 2019 Financial Results Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time PR Newswire
01.05.19 - PR Newswire
Sangamo Therapeutics Announces First Quarter 2019 Conference Call And Webcast
Sangamo Therapeutics Announces First Quarter 2019 Conference Call And Webcast PR Newswire
15.04.19 - PR Newswire
Sangamo Therapeutics Announces Presentations At 2019 Annual Meeting Of The American Society Of Gene & Cell Therapy
Sangamo Therapeutics Announces Presentations At 2019 Annual Meeting Of The American Society Of Gene & Cell Therapy PR Newswire
04.04.19 - PR Newswire
Sangamo Therapeutics Announces Pricing of Public Offering of Common Stock
Sangamo Therapeutics Announces Pricing of Public Offering of Common Stock PR Newswire
03.04.19 - PR Newswire
Sangamo Therapeutics Announces Proposed Public Offering of Common Stock
Sangamo Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire
03.04.19 - Der Aktionär TV
Evotec, MorphoSys, Sangamo - das rät aktuell Marion Schlegel
Marion Schlegel vom Anlegermagazin DER AKTIONÄR blickt in dieser Sendung auf die aktuellen Entwicklungen in der Pharma- und Biotechbranche.
02.04.19 - PR Newswire
Thinking about buying stock in Cronos Group Inc., Facebook Inc., InspireMD Inc., Pulmatrix Inc., or Sangamo Therapeutics?
Thinking about buying stock in Cronos Group Inc., Facebook Inc., InspireMD Inc., Pulmatrix Inc., or Sangamo Therapeutics? PR Newswire
02.04.19 - Der Aktionär TV
US-Markt: Dow Jones, Facebook, Netflix, Lyft, Nio, Tesla, Alibaba, Weibo, Sangamo
Der Dow Jones ließ gestern die 26.000 Punkte-​Marke deutlich hinter sich. Er stieg um 1,2 Prozent an und schloss somit bei 26.241 Zählern. Auch für den S&P 500 und den Nasdaq ...
02.04.19 - PR Newswire
Sangamo Announces Agreement Securing Access To Large-Scale, Commercial-Grade Manufacturing Capacity At Brammer Bio
Sangamo Announces Agreement Securing Access To Large-​Scale, Commercial-​Grade Manufacturing Capacity At Brammer Bio - Balanced in-house and contract manufacturing ...
02.04.19 - PR Newswire
Sangamo Provides Clinical Development Update Including Early Phase 1/2 Beta Thalassemia Gene-edited Cell Therapy Data
Sangamo Provides Clinical Development Update Including Early Phase 1/2 Beta Thalassemia Gene-​edited Cell Therapy Data ‒ Conference call and webcast scheduled for 8:00 a.m. ...
02.04.19 - PR Newswire
Sangamo and Pfizer Announce Phase 1/2 Interim Data For Investigational Hemophilia A Gene Therapy
Sangamo and Pfizer Announce Phase 1/2 Interim Data For Investigational Hemophilia A Gene Therapy - Eight patients treated with SB-525 gene therapy showed dose-​dependent ...

Newssuche

Videos

newspaper
08:20 Uhr +3,64%
Technical Trading: Baumwolle Long, weil...
Cotton Long Typ: Turbo Open End WKN: VP6N8D Hebel: 3,80 Laufzeit: OpenEnd Einstieg: Market ... Mehr »